Article

Negative results of an Italian Group for Mesothelioma (GIMe.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma

Policlinico San Matteo Pavia Fondazione IRCCS, Ticinum, Lombardy, Italy
Cancer Chemotherapy and Pharmacology (Impact Factor: 2.57). 02/2007; 59(1):149-50. DOI: 10.1007/s00280-006-0243-4
Source: PubMed

ABSTRACT Without Abstract

0 Followers
 · 
105 Views
  • Source
    • "Imatinib is a highly selective inhibitor of the bcr/abl mutated tyrosine kinase, as well as of both c-kit and PDGFRs. Several Phase II studies have been conducted with imatinib mesylate in MPM refractory to chemotherapy or chemonaive patients, but negative results were reported (Kumar-Singh et al., 1999; Millward et al., 2003; Villano et al., 2004; Mathy et al., 2005; Porta et al., 2007). In vitro and in vivo experiments demonstrated that STI-571 can cause MPM cell apoptosis and death through inhibition of the AKT/PI3K pathway and that it can also enhances MPM sensitivity to gemcitabine or pemetrexed (Bertino et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor with a poor prognosis. In view of the poor survival benefit from first-line chemotherapy and the lack of subsequent effective treatment options, there is a strong need for the development of more effective treatment approaches for patients with MPM. This review will provide a comprehensive state of the art of new investigational approaches for mesothelioma. In an introductory section, the etiology, epidemiology, natural history, and standard of care treatment for MPM will be discussed. This review provide an update of the major clinical trials that impact mesothelioma treatment, discuss the impact of novel therapeutics, and provide perspective on where the clinical research in mesothelioma is moving. The evidence was collected by a systematic analysis of the literature (2000-2011) using the databases Medline (National Library of Medicine, USA), Embase (Elsevier, Netherlands), Cochrane Library (Great Britain), National Guideline Clearinghouse (USA), HTA Database (International Network of Agencies for Health Technology Assessment - INAHTA), NIH database (USA), International Pleural Mesothelioma Program - WHOLIS (WHO Database), with the following keywords and filters: mesothelioma, guidelines, treatment, surgery, chemotherapy, radiotherapy, review, investigational, drugs. Currently different targeted therapies and biologicals are under investigation for MPM. It is important that the molecular biologic research should first focus on mesothelioma-specific pathways and biomarkers in order to have more effective treatment options for this disease. The use of array technology will be certainly an implicit gain in the identification of new potential prognostic or biomarkers or important pathways in the MPM pathogenesis. Probably a central mesothelioma virtual tissue bank may contribute to the ultimate goal to identify druggable targets and to develop personalized treatment for the MPM patients.
    Frontiers in Oncology 08/2011; 1:22. DOI:10.3389/fonc.2011.00022
  • Advances in insect physiology 01/1998; 27:229-334. DOI:10.1016/S0065-2806(08)60014-4 · 2.68 Impact Factor